Thomas Jefferson University · PharmacologyCalabretta Lab
Bruno Calabretta · Philadelphia, Pennsylvania
Research Focus
Dr. Bruno Calabretta's lab at Thomas Jefferson University focuses on developing innovative treatments for specific types of leukemia, particularly B-cell acute lymphoblastic leukemia (B-ALL). They explore how to 'reprogram' leukemia cells to become less aggressive and more likely to undergo cell maturation and death. The lab uses cutting-edge techniques to inhibit proteins that help leukemia cells proliferate and survive, aiming to improve therapy for patients with resistant forms of leukemia.
leukemiatranscriptional reprogrammingcell differentiationCDK6PROTACsB-ALLcancer therapychromatin dynamicspharmacological inhibitiontyrosine kinase inhibitors
Research Aims
5AIM 01Develop a new strategy to reprogram lymphoid leukemia cells for increased differentiation and apoptosis.
AIM 02Investigate the mechanisms by which leukemic cells resist transcriptional reprogramming.
AIM 03Test the efficacy of pharmacological inhibitors on CDK6 in various leukemia models.
AIM 04Assess how CDK6 degradation affects leukemia cell growth and survival in vivo.
AIM 05Enhance the specificity and efficacy of PROTACs targeting CDK6 for therapeutic use.
Skills the Lab Values
cell culturemouse modelsWestern blotPCRimmunophenotypingchromatin immunoprecipitation (ChIP)small molecule screeningin vivo tumor modelsgene expression analysisbioinformatics
Output against the department
Publications374top 17% of dept.79th of 462
this lab
most publishedleast published
Citations20ktop 17% of dept.78th of 462
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.